Before the Open (Oct 12)

Good morning. Happy Friday.
The Asian/Pacific markets closed with solid gains. China, Hong Kong, South Korea, New Zealand, India, Taiwan, Malaysia and the Philippines did very well. Europe, Africa and the Middle East are currently mostly up. The UK, France, Germany, Denmark, Poland, Turkey, Russia, Greece, South Africa, Finland and Hungary are doing very well; the UAE, Israel and Saudi Arabia are down. Futures in the States point towards a huge gap up for the cash market.
—————
BLOG: CCI – Everything You Need to Know
—————
The dollar is up. Oil and copper are up. Gold and silver are mixed and little changed. Bonds are down.
Overnight Stock Movers from barchart.com…
JPMorgan Chase (JPM -3.00%) is up 1% in pre-market trading after it reported Q3 adjusted EPS of $2.36, higher than consensus of $2.26.
Eastman Chemical (EMN -2.60%) was upgraded to ‘Overweight’ from ‘Neutral’ at JPMorgan Chase with a price target of $95.
IAC/Interactive (IAC +0.80%) was rated a new ‘Buy’ at Nomura Instinet with a price target of $246.
Halliburton (HAL -2.19%) was rated a new ‘Overweight’ at Stephens with a price target of $55.
Match Group (MTCH +1.94%) was rated a new ‘Buy’ at Nomura Instinet with a price target of $66.
Marvell Technology Group Ltd (MRVL +1.96%) was upgraded to ‘Buy’ from ‘Hold’ at Stifel with a price target of $21.
Abeona Therapeutics (ABEO +0.05%) was rated a new ‘Buy’ at Mizuho Securities with a price target of $17.
Corium International (CORI -0.24%) surged 30% in after-hours trading after the company was acquired by Gurnet Point for $12.50 a share.
Two Harbors Investment (TWO -1.59%) was rated a new ‘Outperform’ at Raymond James with a price target of $16.50.
Foamix Pharmaceuticals Ltd (FOMX +0.40%) climbed almost 5% in after-hours trading after it was rated a new ‘Overweight’ at Cantor Fitzgerald with a price target of $15.
Progenics Pharmaceuticals (PGNX -2.79%) rose more than 4% in after-hours trading after it said it will advance its I-131 1095 drug for the treatment of metastatic prostate cancer, into a Phase 2 clinical study.
Tetraphase Pharmaceuticals (TTPH -0.83%) jumped more than 12% in after-hours trading after it announced the commercial launch of its Xerava, a new treatment for intra-abdominal infections.
Immune Design (IMDZ -1.41%) plunged 22% in after-hours trading after it announced that it will discontinue its “Synovate” trial after early analysis of the ongoing Phase 2 trial showed the treatment is not likely to show a survival benefit in relapsed synovial sarcoma patients.
Today’s Economic Calendar
8:30 Import/Export Prices
9:30 Fed’s Evans Speech
10:00 Consumer Sentiment
00:30 PM Fed’s Bostic Speech
1:00 PM Baker-Hughes Rig Count
10:30 PM Randal Quarles Speech
Other…
today’s upgrades/downgrades from briefing.com
this week’s Earnings from Morningstar
this week’s Economic Numbers/Reports powered by ECONODAY